Metrics to compare | EMCU | Peers Peers - average of corresponding metrics from companies closely matching EMCU: MANKIND, GLENMARK, AJANTPHARM, DIVISLAB, ZYDUSLIFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEMCUPeersSector |
|---|---|---|---|---|
P/E Ratio | 36.5x | 36.2x | −0.4x | |
PEG Ratio | 1.01 | 1.37 | 0.00 | |
Price/Book | 7.5x | 6.0x | 2.6x | |
Price / LTM Sales | 3.8x | 5.9x | 3.1x | |
Upside (Analyst Target) | 14.0% | 8.4% | 55.6% | |
Fair Value Upside | Unlock | −2.2% | 7.8% | Unlock |
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.